Exploring Key Insights of the Dry Age Related Macular Degeneration (AMD) Market: Growth Prospects, Emerging Trends, and Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the dry age related macular degeneration (amd) market grown over the years?
In recent years, the market size for dry age related macular degeneration (AMD) has witnessed robust growth. The market is forecasted to expand from $4.49 billion in 2024 to $4.90 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.1%. The surge during the historic period can be traced back to an increasing elderly population, higher incidence of chronic diseases, heightened awareness about ocular health, a rise in clinical trials centered around dry AMD, and greater demand for less invasive procedures.
What Is the forecasted market size and growth rate for the dry age related macular degeneration (amd) market?
The market for dry age related macular degeneration (AMD) is predicted to experience significant expansion in the coming years. It is projected to reach a value of $6.86 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.8%. Factors such as the introduction of innovative therapies, an increase in healthcare spending, growing use of laser photocoagulation therapy, breakthroughs in genetic research and an emphasis on personalized treatment are likely to drive this growth within the forecast period. The period is also expected to witness trends such as advancements in diagnostic technologies, wider adoption of teleophthalmology, state-of-the-art treatments, approval of products, and the launch of new products.
Get your dry age related macular degeneration (amd) market report here!
What are the major factors driving growth in the dry age related macular degeneration (amd) market?
The surge in the elderly population is anticipated to drive the expansion of the dry age-related macular degeneration (AMD) market. The term “geriatric population” refers to individuals who are typically 65 years old or above. The escalation in the number of older adults is due to several contributing factors such as advancements in medical technology, successful handling of chronic illnesses, increased life expectancy, and elevated quality of geriatric care. Dry age-related macular degeneration (AMD) benefits these seniors by offering custom-made treatments and management strategies designed to decelerate the disease’s advance, conserve sight and enhance the quality of life for those affected by this condition. For example, as per the reports circulated by the National Council on Aging, based in the U.S, in 2022, an estimated 57.8 million adults were aged 65 or above, accounting for 17.3% of the total U.S population. This showcased an uptick from 16.9% in 2021. Hence, the increasing geriatric population is projected to fuel the growth of the dry age-related macular degeneration (AMD) market.
What key areas define the segmentation of the global dry age related macular degeneration (amd) Market?
The dry age related macular degeneration (AMD) market covered in this report is segmented –
1) By Stages: Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration
2) By Age Group: Above 75 Years, Above 60 Years, Above 40 Years
3) By Route Of Administration: Oral, Injectables
4) By End Users: Hospitals And Clinics, Diagnostic Centers, Academic And Research Institutes
Subsegments:
1) By Early Age-Related Macular Degeneration: Drusen Accumulation, Retinal Pigment Epithelium Changes
2) By Intermediate Age-Related Macular Degeneration: Larger Drusen Deposits, Increased Pigmentary Abnormalities
3) By Late Age-Related Macular Degeneration: Geographic Atrophy, Central Vision Loss
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21176&type=smp
What are the top market players propelling the growth of the dry age related macular degeneration (amd) industry?
Major companies operating in the dry age related macular degeneration (AMD) market are F Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Amgen Inc., Biogen Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Lupin Ltd., Santen Pharmaceuticals Inc., Biocon Ltd., Alimera Sciences Inc., Apellis Pharmaceuticals Inc., Belite Bio Inc., Axol Bioscience Ltd., Alkeus Pharmaceuticals Inc., Kubota Holdings Co., Ribomic Inc., Eyestem Research Pvt. Ltd., LumiThera Inc., Adverum Biotechnologies Inc.
What are the key trends shaping the future of the dry age related macular degeneration (amd) market?
Primary businesses in the dry age-related macular degeneration (AMD) sector are concentrating on the creation of novel, advanced technologies and remedies, such as light delivery systems. These are intended to target and stimulate retinal cells, potentially reducing the progression of the disease. Light delivery systems pertain to technologies crafted for the transmission of light in therapeutic procedures, most notably in medical treatments. For instance, LumiThera Inc., a medical device firm based in the US, unveiled photobiomodulation (PBM) for dry AMD through the Valeda Light Delivery System in January 2024. This marked the first therapy sanctioned by the FDA specifically designed to counter vision loss in patients afflicted by dry AMD, a disease with currently restricted treatment alternatives. LumiThera initiated the EUROLIGHT registry study to compile long-term data on patient outcomes post-treatment with the Valeda system. The Valeda system uses a light delivery procedure with three specific wavelengths (590 nm, 660 nm, and 850 nm). This non-invasive therapy can be delivered either through an open or shut eyelid and usually necessitates nine sessions over a span of three to four weeks.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21176
What regions are dominating the dry age related macular degeneration (amd) market growth?
North America was the largest region in the dry age-related macular degeneration (AMD) market in 2024. The regions covered in the dry age related macular degeneration (AMD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Hyperuricemia Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hyperuricemia-drugs-global-market-report
Gout Therapeutics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/gout-therapeutics-global-market-report
Smart Insulin Pens Global Market Report 2025
https://thebusinessresearchcompany.com/report/smart-insulin-pens-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
